FI970301A - Spesifisen immunoglobuliinin määrittäminen käyttäen useampaa antigeenia - Google Patents

Spesifisen immunoglobuliinin määrittäminen käyttäen useampaa antigeenia Download PDF

Info

Publication number
FI970301A
FI970301A FI970301A FI970301A FI970301A FI 970301 A FI970301 A FI 970301A FI 970301 A FI970301 A FI 970301A FI 970301 A FI970301 A FI 970301A FI 970301 A FI970301 A FI 970301A
Authority
FI
Finland
Prior art keywords
solid phase
antibody
determination
antigens
multiple antigens
Prior art date
Application number
FI970301A
Other languages
English (en)
Swedish (sv)
Other versions
FI970301A0 (fi
Inventor
Ursula-Henrike Wienhues
Cornelia Kruse-Mueller
Eva Hoess
Elke Faatz
Beatus Ofenloch-Haehnle
Christoph Seidel
Michael Wiedmann
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4430972A external-priority patent/DE4430972A1/de
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of FI970301A0 publication Critical patent/FI970301A0/fi
Publication of FI970301A publication Critical patent/FI970301A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
FI970301A 1994-07-25 1997-01-24 Spesifisen immunoglobuliinin määrittäminen käyttäen useampaa antigeenia FI970301A (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4426276 1994-07-25
DE4430972A DE4430972A1 (de) 1994-07-25 1994-08-31 Bestimmung von spezifischem Immunglobulin unter Verwendung multipler Antigene
PCT/EP1995/002919 WO1996003652A1 (de) 1994-07-25 1995-07-24 Bestimmung von spezifischem immunglobulin unter verwendung multipler antigene

Publications (2)

Publication Number Publication Date
FI970301A0 FI970301A0 (fi) 1997-01-24
FI970301A true FI970301A (fi) 1997-03-24

Family

ID=25938668

Family Applications (1)

Application Number Title Priority Date Filing Date
FI970301A FI970301A (fi) 1994-07-25 1997-01-24 Spesifisen immunoglobuliinin määrittäminen käyttäen useampaa antigeenia

Country Status (13)

Country Link
US (3) US6613530B1 (fi)
EP (1) EP0772774B1 (fi)
JP (1) JP3556228B2 (fi)
CN (1) CN1148578C (fi)
AT (1) ATE331952T1 (fi)
AU (1) AU688953B2 (fi)
CA (1) CA2195753C (fi)
DE (1) DE59511054D1 (fi)
ES (1) ES2268694T3 (fi)
FI (1) FI970301A (fi)
NO (1) NO970292L (fi)
NZ (1) NZ291153A (fi)
WO (1) WO1996003652A1 (fi)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0772774B1 (de) * 1994-07-25 2006-06-28 Roche Diagnostics GmbH Bestimmung von spezifischem immunglobulin unter verwendung multipler antigene
DE19649389A1 (de) 1996-11-29 1998-06-04 Boehringer Mannheim Gmbh Antigenspezifischer IgM-Nachweis
WO1998040744A1 (de) 1997-03-10 1998-09-17 Roche Diagnostics Gmbh Verfahren zur simultanen bestimmung von hiv-antigenen und hiv-antikörpern
EP0922958B1 (de) * 1997-12-11 2002-10-02 Roche Diagnostics GmbH Entstörung von diagnostischen Verfahren durch Peptide aus D-Aminosäuren
US20050106137A1 (en) * 2000-05-05 2005-05-19 Stephen Grimes Chimeric peptide immunogens
US7897404B2 (en) 2000-09-29 2011-03-01 Roche Diagnostics Operations, Inc. Conjugates of defined stoichiometry
DE10048417A1 (de) * 2000-09-29 2002-04-11 Roche Diagnostics Gmbh Verbindungen mit verzweigtem Linker
US6818392B2 (en) 2000-12-06 2004-11-16 Abbott Laboratories Monoclonal antibodies to human immunodeficiency virus and uses thereof
JP2005508838A (ja) 2001-03-23 2005-04-07 アフトン コーポレーション 膵癌の組合せ治療
US20090191232A1 (en) 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
CA2452208C (en) 2001-08-10 2010-01-26 F. Hoffmann-La Roche Ag Method for producing microparticles loaded with proteins
US7235376B2 (en) * 2003-03-28 2007-06-26 Receptor Biologix, Inc. Gastrin hormone immunoassays
US7851209B2 (en) * 2003-04-03 2010-12-14 Kimberly-Clark Worldwide, Inc. Reduction of the hook effect in assay devices
JP2007505320A (ja) * 2003-09-11 2007-03-08 アイデックス ラボラトリーズ インコーポレイテッド ネコ免疫不全ウイルスの検出のための方法と装置
WO2006011919A1 (en) * 2004-06-30 2006-02-02 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
CA2550264C (en) * 2003-12-18 2011-06-28 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
CA2556141A1 (en) * 2004-02-19 2005-09-01 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
WO2006011917A1 (en) * 2004-06-30 2006-02-02 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
JP4866848B2 (ja) * 2004-06-30 2012-02-01 アイデックス ラボラトリーズ インコーポレイテッド ネコ免疫不全ウイルス（ｆｉｖ）のｅｎｖタンパク質のｖ３領域に由来するペプチドの使用を含むｆｉｖを検出するための方法および装置
EP1794586B1 (en) 2004-09-22 2013-01-30 Cancer Advances, Inc., Monoclonal antibodies to progastrin
US7291338B2 (en) * 2005-03-09 2007-11-06 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
US8865398B2 (en) 2006-09-01 2014-10-21 Abbott Laboratories Combination hepatitis C virus antigen and antibody detection method
EP1978365B1 (en) 2007-03-16 2010-08-25 Sysmex Corporation Reagent kit and method for measuring HCV antibody
ES2372359T3 (es) * 2007-04-20 2012-01-19 F. Hoffmann-La Roche Ag Detección de infecciones primarias por patógenos.
AU2009239558B2 (en) * 2008-04-21 2013-05-02 Bio-Rad Laboratories, Inc. Recombinant deamidated gliadin antigen
WO2010085548A2 (en) * 2009-01-22 2010-07-29 Li-Cor, Inc. Single molecule proteomics with dynamic probes
US8586347B2 (en) 2010-09-15 2013-11-19 Mbio Diagnostics, Inc. System and method for detecting multiple molecules in one assay
EP3187585A1 (en) 2010-03-25 2017-07-05 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
WO2011123781A1 (en) 2010-04-02 2011-10-06 Idexx Laboratories, Inc. Detection of feline immunodeficiency virus
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
CN104254777B (zh) 2011-12-05 2016-08-24 伯乐实验室公司 重组脱酰胺化麦醇溶蛋白抗原
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US20210132061A1 (en) * 2017-04-14 2021-05-06 The Regents Of The University Of California Methods and Devices for Performing Auto-Antibody Assays
JP7469225B2 (ja) 2017-06-15 2024-04-16 キャンサー アドヴァンシーズ インク． 腫瘍及び癌に対する体液性及び細胞性免疫を誘発するための組成物及び方法
CN110456073B (zh) * 2019-08-21 2023-09-22 广东菲鹏生物有限公司 双抗原夹心检测抗体的方法及试剂盒

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837167A (en) * 1981-01-30 1989-06-06 Centocor, Inc. Immunoassay for multi-determinant antigens using high-affinity
GR850899B (fi) 1984-04-12 1985-11-25 Gen Hospital Corp
DK365785A (da) * 1984-09-17 1986-03-18 Hoffmann La Roche Metalcomplexer
EP0366673B1 (en) * 1987-06-09 1992-09-16 Cambridge Life Sciences Plc Immunoassay method
AU1732988A (en) 1987-08-20 1989-02-23 Mooney Chemicals, Inc. High-solids coating compositions
PT88416B (pt) * 1987-09-04 1992-10-30 Wellcome Found Processo para determinacao imunologica de anticorpos e processo para a preparacao de uma proteina com capacidade de ligacao a anticorpos e de composicoes farmaceuticas que a contem
JPH01163661A (ja) * 1987-10-02 1989-06-27 E I Du Pont De Nemours & Co ＩｇＧ捕捉抗体および多重単クローン性抗体検出系を用いたイムノアツセイ
EP0339695A3 (en) * 1988-04-29 1990-05-30 Stichting Voor De Technische Wetenschappen A process for preparing an antigenic or immunogenic conjugate as well as the use of such conjugates
WO1990007119A1 (en) * 1988-12-20 1990-06-28 Immunodiagnostics, Inc. Synthetic hiv-like peptides, their compositions and uses
JPH02290554A (ja) 1989-02-09 1990-11-30 Meidensha Corp 酵素免疫測定試薬およびその調製方法
CA1340530C (en) 1989-04-28 1999-05-04 Kok Kheong Lee Synthetic pseudomonas aeruginosa pilin peptide and related vaccines and diagnostics
DE69032383T2 (de) * 1989-08-04 1998-12-10 Behringwerke AG, 35041 Marburg Heterogene Bindungstests
JPH0389163A (ja) 1989-08-31 1991-04-15 Meidensha Corp 酵素免疫測定用試薬及びその調製方法
JPH0389165A (ja) 1989-08-31 1991-04-15 Meidensha Corp 酵素免疫測定用試薬及びその調製方法
JPH0389164A (ja) 1989-08-31 1991-04-15 Meidensha Corp 酵素免疫測定用試薬及びその調製方法
EP0507587A3 (en) 1991-04-03 1993-03-03 Syntex (U.S.A.) Inc. Immunoassay for immunoglubulins
JPH05133952A (ja) * 1991-04-03 1993-05-28 Syntex Usa Inc イムノグロブリン類のイムノアツセイ
RU2212899C2 (ru) 1991-09-13 2003-09-27 Чирон Корпорейшн Hcv иммунореактивные полипептидные композиции
US5618533A (en) * 1992-02-11 1997-04-08 Yale University Flagellin-based polypeptides for the diagnosis of lyme disease
US5304371A (en) * 1992-02-14 1994-04-19 Lasys Corporation Peptide for diagnosing and immunizing against T. cruzi infection
US5580563A (en) * 1992-05-01 1996-12-03 Tam; James P. Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof
US6660276B1 (en) 1994-02-16 2003-12-09 The University Of Virginia Patent Foundation Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
WO1996003423A1 (de) * 1994-07-25 1996-02-08 Boehringer Mannheim Gmbh Hapten-markierte peptide
EP0772774B1 (de) * 1994-07-25 2006-06-28 Roche Diagnostics GmbH Bestimmung von spezifischem immunglobulin unter verwendung multipler antigene
DE19723463A1 (de) * 1997-06-04 1998-12-10 Dade Behring Marburg Gmbh Immunchemische Bestimmung von multivalenten Analyten

Also Published As

Publication number Publication date
CN1157655A (zh) 1997-08-20
NO970292L (no) 1997-03-13
ATE331952T1 (de) 2006-07-15
NO970292D0 (no) 1997-01-23
US20100136519A1 (en) 2010-06-03
CN1148578C (zh) 2004-05-05
EP0772774B1 (de) 2006-06-28
JP3556228B2 (ja) 2004-08-18
AU688953B2 (en) 1998-03-19
JPH10504539A (ja) 1998-05-06
CA2195753C (en) 2008-12-16
US20050074750A1 (en) 2005-04-07
ES2268694T3 (es) 2007-03-16
DE59511054D1 (de) 2006-08-10
AU3220495A (en) 1996-02-22
US7629295B2 (en) 2009-12-08
WO1996003652A1 (de) 1996-02-08
CA2195753A1 (en) 1996-02-08
NZ291153A (en) 1999-01-28
US6613530B1 (en) 2003-09-02
FI970301A0 (fi) 1997-01-24
EP0772774A1 (de) 1997-05-14

Similar Documents

Publication Publication Date Title
FI970301A (fi) Spesifisen immunoglobuliinin määrittäminen käyttäen useampaa antigeenia
DK1232392T3 (da) Forbedret fremgangsmåde til påvisning af syreresistente bakterier af slægten Helicobacter i afføring
EP0315364A3 (en) Simultaneous immunoassay for the determination of antigens and antibodies
ES8206856A1 (es) Mejoras en un metodo y su correspondiente equipo de ensayo para determinar antigenos por medio de una reaccion inmuno- quimica
EP0375422A3 (en) Composition and methods for determining the presence of amphetamines in a sample suspected of containing amphetamine and/or methamphetamine
DK165785A (da) Immunometrisk bestemmelse rettet mod flere steder
EP0310132A3 (en) Immunoassay utilizing igg capture antibody and multiple monoclonal antibody detection system
DE59511101D1 (de) Metallchelat-markierte peptide
KR850002385A (ko) PIVKA-Ⅱ의 측정(assay)용 방법 및 시약
PT902286E (pt) Imunoensaio utilizando duas incubacoes com antigenios marcados
EP0100955A3 (en) Monoclonal immunoglobulin m antibodies and method of preparation
ES2061324T3 (es) Complejo aglutinante como reactivo de identificacion de grupo sanguineo.
DE59109139D1 (de) Immunologischer Nachweis von Metolachlor
ES2131279T3 (es) Inmunoensayo de tipo sandwich para n-peptido.
ES552074A0 (es) Un metodo en emparedado de doble anticuerpo para detectar o ensayar un antigeno seleccionado de urocinasa humana y un precursor de la misma
NO903820D0 (no) Fremgangsmaate for paavisning av analytter.
DK0463998T3 (da) Immunologisk påvisningsfremgangsmåde for triasulforon.

Legal Events

Date Code Title Description
HC Name/ company changed in application

Owner name: ROCHE DIAGNOSTICS GMBH

MA Patent expired